Back to Search Start Over

[Questions--answers on the use of rivaroxaban for the treatment of venous thromboembolic disease].

Authors :
Pernod G
Elias A
Gouin I
Gaillard C
Nguyen P
Ouvry P
Sié P
Source :
Journal des maladies vasculaires [J Mal Vasc] 2012 Dec; Vol. 37 (6), pp. 300-10. Date of Electronic Publication: 2012 Nov 02.
Publication Year :
2012

Abstract

Rivaroxaban is a direct oral anticoagulant targeting factor Xa. Efficacy and safety of rivaroxaban were evaluated through the phase 3 EINSTEIN program, consisting in three clinical trials regarding the treatment of deep vein thrombosis (EINSTEIN DVT), pulmonary embolism (EINSTEIN PE), and in secondary prevention after a first episode of venous thromboembolic disease (EISNTEIN EXT). Rivaroxaban was recently approved both by the European and the French Health agencies for the treatment of DVT and prevention of deep vein thrombosis recurrence. This report addresses the use of rivaroxaban in clinical practice in such indications.<br /> (Copyright © 2012 Elsevier Masson SAS. All rights reserved.)

Details

Language :
French
ISSN :
2214-8116
Volume :
37
Issue :
6
Database :
MEDLINE
Journal :
Journal des maladies vasculaires
Publication Type :
Academic Journal
Accession number :
23122646
Full Text :
https://doi.org/10.1016/j.jmv.2012.09.003